New research shows that semaglutide, the compound in the weight-loss drug Wegovy, could treat an increasingly common liver disease. The study, published Wednesday in the New England Journal of Medicine, included 800 adults with a severe form of liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH. People develop MASH after fat builds up in…
The Trump administration on Friday rejected a Biden plan that would have required Medicare and Medicaid to cover obesity drugs and expanded access for millions of people. Under the law that established Medicare’s Part D drug benefits, the program was forbidden from paying for drugs for “weight loss.” But the Biden administration’s proposal last November…
It’s easy to make a medical case for blockbuster weight loss drugs like Wegovy and Zepbound, which have been shown to prevent heart attacks and strokes and save lives. But for the employers and government programs being asked to pay for the medications, the financial case for them is less clear. Are the drugs’ benefits…